Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

Rhea-AI Summary

Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its second quarter 2025 financial results announcement for August 5, 2025, at 8:00 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the company's website. A replay will be available at www.curis.com.

LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the events & presentations section of the Curis website. A replay of the conference call will be available at www.curis.com.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-second-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-5-2025-302515476.html

SOURCE Curis, Inc.

FAQ

When will Curis (CRIS) report Q2 2025 earnings?

Curis will report its Q2 2025 financial results on Tuesday, August 5, 2025, at 8:00 a.m. ET.

How can investors access Curis (CRIS) Q2 2025 earnings call?

Investors can join by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations, or access the live webcast through Curis's website.

What time is Curis (CRIS) Q2 2025 earnings conference call?

The conference call and webcast will be held on August 5, 2025, at 8:30 a.m. ET.

What is Curis's main product in development?

Curis is developing emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor.